Long-lasting remission after rituximab treatment in a case of anti-Hu-associated sensory neuronopathy and gastric pseudoobstruction

Journal of Neuro-Oncology

Volumn 93, Issue 3, 2009, Pages 421-423

  Coret, Francisco ^a   Bosca, Isabel ^b   Fratalia, Loren ^a   Perez Griera, Jaume ^a   Pascual, Ana ^b   Casanova, Bonaventura ^b  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Anti Hu antibodies; Paraneoplastic neurological syndromes; Rituximab; Therapy

Indexed keywords

HU ANTIBODY; IMMUNOGLOBULIN; RITUXIMAB; STEROID;

ABSENCE OF SIDE EFFECTS; ADULT; ANAMNESIS; ANTIBODY TITER; ARTICLE; CASE REPORT; CHEMOTHERAPY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG TREATMENT FAILURE; ELECTRONEUROGRAPHY; FEMALE; GENERAL CONDITION IMPROVEMENT; HUMAN; INTESTINE MOTILITY; LEUKOARAIOSIS; MALIGNANT NEOPLASTIC DISEASE; MYOTATIC REFLEX; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; REMISSION; SENSORY NEUROPATHY; STOMACH BIOPSY; STOMACH DISTENSION; STOMACH OBSTRUCTION; STOMACH PARESIS; STOMACH PSEUDOOBSTRUCTION; WALKING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; AUTOANTIBODIES; FEMALE; HU PARANEOPLASTIC ENCEPHALOMYELITIS ANTIGENS; HUMANS; INTESTINAL PSEUDO-OBSTRUCTION; MIDDLE AGED; PARANEOPLASTIC SYNDROMES, NERVOUS SYSTEM; POLYRADICULONEUROPATHY; REMISSION INDUCTION; STOMACH DISEASES;

EID: 67349141484     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-008-9787-y     Document Type: Article

References (13)

1. Graus F, Keime-Guibert F, Reñe R et al (2001) Anti-Hu-associated paraneoplastic encephalomyelitis: Analysis of 200 patients. Brain 124:1138-1148. doi: 10.1093/brain/124.6.1138
2. Lladó A, Carpentier AF, Honnorat J et al (2006) Hu-antibody-positive patients with or without cancer have similar clinical profiles. J Neurol Neurosurg Psychiatry 77:996-997. doi: 10.1136/jnnp.2005.085753
3. Szabo A, Dalmau J, Manley G et al (1991) HuD, a paraneoplastic encephalomyelitis antigen, contains RNA-binding domains and is homologous to Elav and Sex-lethal. Cell 67:325-333. doi: 10.1016/ 0092-8674(91)90184-Z
4. Honnorat J, Cartalat-Carel S (2004) Advances in paraneoplastic neurological syndromes. Curr Opin Oncol 16:614-620. doi: 10.1097/ 01.cco.0000142486.89472.eb
5. Esposito M, Penza P, Orefice G et al (2008) Successful treatment of paraneoplastic cerebellar degeneration with Rituximab. J Neurooncol 86:363-364. doi: 10.1007/s11060-007-9479-z
6. Shams'ili S, Beukelaar J, Willem Gratama J et al (2006) An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. J Neurol 253:16-20. doi: 10.1007/s00415-005-0882-0
7. Byrne T, Mason WP, Posner JB, Dalmau J (1997) Spontaneous neurological improvement in anti-Hu associated encephalomyelitis. J Neurol Neurosurg Psychiatry 62:276-278. doi: 10.1136/jnnp.62.3.276
8. Lladó A, Mannucci P, Carpentier AF et al (2004) Value of Hu antibody determinations in the follow-up of paraneoplastic neurologic syndromes. Neurology 63:1947-1949
9. Darnell JC, Posner JB (2003) Paraneoplastic syndromes involving the nervous system. N Engl J Med 349:1543-1554. doi: 10.1056/NEJMra023009
10. Graus F, Illa I, Agusti M, Ribalta T et al (1991) Effect of intraventricular injection of an anti-Purkinje cell antibody (anti-Yo) in a guinea pig model. J Neurol Sci 106:82-87. doi: 10.1016/ 0022-510X(91)90198-G
11. Gonzalez-Stawinski GV, Yu PB, Love SD et al (2001) Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody. Clin Immunol 98:175-179. doi: 10.1006/ clim.2000.4980
12. Arzoo K, Sadeghi S, Liebman HA (2002) Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab). Ann Rheum Dis 61:922-924. doi: 10.1136/ard.61.10.922
13. Graus F, Dalmau J (2007) Paraneoplastic neurological syndromes: diagnosis and treatment. Curr Opin Neurol 20:732-737